SDGR vs. BBIO, LNTH, RVMD, LEGN, ELAN, CYTK, NUVL, AXSM, TGTX, and GRFS
Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include BridgeBio Pharma (BBIO), Lantheus (LNTH), Revolution Medicines (RVMD), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.
Schrödinger vs.
BridgeBio Pharma (NASDAQ:BBIO) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk, institutional ownership and community ranking.
In the previous week, BridgeBio Pharma had 8 more articles in the media than Schrödinger. MarketBeat recorded 15 mentions for BridgeBio Pharma and 7 mentions for Schrödinger. BridgeBio Pharma's average media sentiment score of 0.38 beat Schrödinger's score of 0.31 indicating that BridgeBio Pharma is being referred to more favorably in the media.
BridgeBio Pharma presently has a consensus target price of $49.00, suggesting a potential upside of 43.23%. Schrödinger has a consensus target price of $32.11, suggesting a potential upside of 28.03%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Schrödinger.
Schrödinger has a net margin of -91.84% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Schrödinger's return on equity.
99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 79.1% of Schrödinger shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 8.6% of Schrödinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BridgeBio Pharma received 114 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 71.19% of users gave BridgeBio Pharma an outperform vote while only 57.45% of users gave Schrödinger an outperform vote.
Schrödinger has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Schrödinger has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Summary
BridgeBio Pharma beats Schrödinger on 11 of the 19 factors compared between the two stocks.
Get Schrödinger News Delivered to You Automatically
Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Schrödinger Competitors List
Related Companies and Tools
This page (NASDAQ:SDGR) was last updated on 2/1/2025 by MarketBeat.com Staff
